Clinical Trial Update: Empagliflozin for the Treatment of Postprandial Hypoglycemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating empagliflozin for postprandial hypoglycemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postprandial Hypoglycemia

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Postprandial Hypoglycemia | Phase 3 | Status: TERMINATED